BioSpace News Archive

Fact.MR, a market research and competitive intelligence provider, has conducted a complete analysis on the global coronary stents market, which is projected to rise at a prolific CAGR of 12.9% over the forecast period.

Wilmington, Delaware, United States: Cold plasma, popularly known as non-thermal plasma, is the new cutting edge concept that has wide applications in medical devices.

Wilmington, Delaware, United States: The global oncology biosimilars market is prophesied in a report by Transparency Market Research finds highly competitive and highly fragmentation owing to presence of strong players in the market.

Fact.MR – A Market Research and Competitive Intelligence Provider: Demand for medical waste management is anticipated to rise at a CAGR of 6.2% from 2021 to 2028.

Wilmington, Delaware, United States: Mass spectrometry is a powerful analytical technique in the field of life sciences.

89bio, Inc. announced the pricing of its previously announced underwritten public offering of 18,675,466 shares of its common stock and accompanying warrants to purchase up to 9,337,733 shares of common stock at a combined public offering price of $3.55.

Mentice, Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced that Medtronic, Dublin, a global healthcare technology leader, has signed an agreement to acquire Mentice VIST® simulation solutions and development services, in an initial order of USD 1.93 million.

ReCode Therapeutics announced the close of a Series B extension financing round, co-led by new investors, Leaps by Bayer, the impact investment unit of Bayer AG, AyurMaya, an affiliate of Matrix Capital Management, and with participation from Amgen Ventures.

MolecuLight Inc.announces that it has received an expansion to its FDA 510 clearance for the MolecuLight i:X® imaging device’s ability to detect the location of elevated bacterial loads in wounds.

Eli Lilly and Company announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately $275 million.